Transport of asymmetric dimethylarginine (ADMA) by cationic amino acid transporter 2 (CAT2), organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1)

Amino Acids

Volumn 45, Issue 4, 2013, Pages 989-1002

  Strobel, Joachim ^a   Müller, Fabian ^a   Zolk, Oliver ^a   Endreß, Beate ^a   König, Jörg ^a   Fromm, Martin F ^a   Maas, Renke ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

ADMA; Asymmetric dimethylarginine; Cationic amino acid transporter 2; l Arginine; Multidrug and toxin extrusion protein 1; Organic cation transporter 2

Indexed keywords

AMINO ACID TRANSPORTER; ARGININE; MEMBRANE PROTEIN; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; N(G),N(G) DIMETHYLARGININE; ORGANIC CATION TRANSPORTER 2; UNCLASSIFIED DRUG;

AMINO ACID TRANSPORT; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; KINETICS; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ARGININE; CELLS, CULTURED; GENE EXPRESSION PROFILING; HEK293 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; ORGANIC CATION TRANSPORT PROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; REAL-TIME POLYMERASE CHAIN REACTION; TRPV CATION CHANNELS;

EID: 84885328397     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-013-1556-3     Document Type: Article

References (53)

1. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P (2003) Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23(8):1455-1459. doi: 10.1161/01.ATV.0000081742.92006.59
2. Barendt WM, Wright SH (2002) The human organic cation transporter (hOCT2) recognizes the degree of substrate ionization. J Biol Chem 277(25):22491-22496. doi: 10.1074/jbc.M203114200
3. Baydoun AR, Emery PW, Pearson JD, Mann GE (1990) Substrate-dependent regulation of intracellular amino acid concentrations in cultured bovine aortic endothelial cells. Biochem Biophys Res Commun 173(3):940-948. doi: 10.1016/S0006-291X(05)80876-9
4. Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, Schulze F, Xanthakis V, Benndorf RA, Vasan RS (2009) Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 119(12):1592-1600. doi: 10.1161/CIRCULATIONAHA.108.838268
5. Bronk JR, Fisher RB (1956) The role of ornithine and citrulline in urea synthesis. Biochem J 64(1):111-118
6. Cardounel AJ, Cui H, Samouilov A, Johnson W, Kearns P, Tsai AL, Berka V, Zweier JL (2007) Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 282(2):879-887. doi: 10.1074/jbc.M603606200
7. Carnegie PR, Fellows FC, Symington GR (1977) Urinary excretion of methylarginine in human disease. Metabolism 26(5):531-537
8. Closs EI, Albritton LM, Kim JW, Cunningham JM (1993) Identification of a low affinity, high capacity transporter of cationic amino acids in mouse liver. J Biol Chem 268(10):7538-7544
9. Closs EI, Basha FZ, Habermeier A, Förstermann U (1997a) Interference of l-arginine analogues with l-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1(1):65-73. doi: 10.1006/niox.1996.0106
10. Closs EI, Gräf P, Habermeier A, Cunningham JM, Förstermann U (1997b) Human cationic amino acid transporters hCAT-1, hCAT-2A, and hCAT-2B: three related carriers with distinct transport properties. Biochemistry 36(21):6462-6468. doi: 10.1021/bi962829p
11. Closs EI, Scheld JS, Sharafi M, Förstermann U (2000) Substrate supply for nitric-oxide synthase in macrophages and endothelial cells: role of cationic amino acid transporters. Mol Pharmacol 57(1):68-74
12. Closs EI, Boissel JP, Habermeier A, Rotmann A (2006) Structure and function of cationic amino acid transporters (CATs). J Membr Biol 213(2):67-77. doi: 10.1007/s00232-006-0875-7
13. Closs EI, Ostad MA, Simon A, Warnholtz A, Jabs A, Habermeier A, Daiber A, Förstermann U, Münzel T (2012) Impairment of the extrusion transporter for asymmetric dimethyl-l-arginine: a novel mechanism underlying vasospastic angina. Biochem Biophys Res Commun 423(2):218-223. doi: 10.1016/j.bbrc.2012.05.044
14. Cui Y, König J, Buchholz JK, Spring H, Leier I, Keppler D (1999) Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55(5):929-937
15. De Nicola L, Blantz RC, Gabbai FB (1992) Nitric oxide and angiotensin II. Glomerular and tubular interaction in the rat. J Clin Invest 89(4):1248-1256. doi: 10.1172/JCI115709
16. Diaz-Perez F, Radojkovic C, Aguilera V, Veas C, Gonzalez M, Lamperti L, Escudero C, Aguayo C (2012) l-Arginine transport and nitric oxide synthesis in human endothelial progenitor cells. J Cardiovasc Pharmacol 60(5):439-449. doi: 10.1097/FJC.0b013e318269ae2f
17. Dioguardi FS (2011) To give or not to give? Lessons from the arginine paradox. J Nutrigenet Nutrigenomics 4(2):90-98
18. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Böger SM, Haller H, Ritz E (2005) Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 16(8):2456-2461. doi: 10.1681/ASN.2005020179
19. Hingorani AD (2001) Polymorphisms in endothelial nitric oxide synthase and atherogenesis: John French Lecture 2000. Atherosclerosis 154(3):521-527
20. Kavanaugh MP, Wang H, Zhang Z, Zhang W, Wu YN, Dechant E, North RA, Kabat D (1994) Control of cationic amino acid transport and retroviral receptor functions in a membrane protein family. J Biol Chem 269(22):15445-15450
21. Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D, Frölich JC, Hoeper MM, Haller H, Fliser D (2004) Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109(2):172-177. doi: 10.1161/01.CIR.0000105764.22626.B1
22. Kitiyakara C, Chabrashvili T, Jose P, Welch WJ, Wilcox CS (2001) Effects of dietary salt intake on plasma arginine. Am J Physiol Regul Integr Comp Physiol 280(4):R1069-R1075
23. Koepsell H, Lips K, Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24(7):1227-1251. doi: 10.1007/s11095-007-9254-z
24. König J, Zolk O, Singer K, Hoffmann C, Fromm MF (2011) Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. Br J Pharmacol 163(3):546-555. doi: 10.1111/j.1476-5381.2010.01052.x
25. Mann GE, Yudilevich DL, Sobrevia L (2003) Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 83(1):183-252. doi: 10.1152/physrev.00022.2002
26. Mateus A, Matsson P, Artursson P (2013) Rapid measurement of intracellular unbound drug concentrations. Mol Pharm. doi: 10.1021/mp4000822
27. Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB (2010) Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol 298(4):F997-F1005. doi: 10.1152/ajprenal.00431.2009
28. Müller F, König J, Glaeser H, Schmidt I, Zolk O, Fromm MF, Maas R (2011) Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother 55(7):3091-3098. doi: 10.1128/AAC.01835-10
29. Nicholson B, Manner CK, Kleeman J, MacLeod CL (2001) Sustained nitric oxide production in macrophages requires the arginine transporter CAT2. J Biol Chem 276(19):15881-15885. doi: 10.1074/jbc.M010030200
30. Nickovic V, Nikolic J, Djindjic N, Ilic M, Nickovic J, Mladenovic D, Krstic N (2012) Diagnostical significance of dimethylarginine in the development of hepatorenal syndrome in patients with alcoholic liver cirrhosis. Vojnosanit Pregl 69(8):686-691
31. Nijveldt RJ, Van Leeuwen PA, Van Guldener C, Stehouwer CD, Rauwerda JA, Teerlink T (2002) Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol Dial Transplant 17(11):1999-2002
32. Ohta KY, Imamura Y, Okudaira N, Atsumi R, Inoue K, Yuasa H (2009) Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones. J Pharmacol Exp Ther 328(2):628-634. doi: 10.1124/jpet.108.142257
33. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y (2005) A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA 102(50):17923-17928. doi: 10.1073/pnas.0506483102
34. Palm F, Friederich M, Carlsson PO, Hansell P, Teerlink T, Liss P (2008) Reduced nitric oxide in diabetic kidneys due to increased hepatic arginine metabolism: implications for renomedullary oxygen availability. Am J Physiol Renal Physiol 294(1):F30-F37. doi: 10.1152/ajprenal.00166.2007
35. Perkins CP, Mar V, Shutter JR, del Castillo J, Danilenko DM, Medlock ES, Ponting IL, Graham M, Stark KL, Zuo Y, Cunningham JM, Bosselman RA (1997) Anemia and perinatal death result from loss of the murine ecotropic retrovirus receptor mCAT-1. Genes Dev 11(7):914-925
36. Pietig G, Mehrens T, Hirsch JR, Cetinkaya I, Piechota H, Schlatter E (2001) Properties and regulation of organic cation transport in freshly isolated human proximal tubules. J Biol Chem 276(36):33741-33746. doi: 10.1074/jbc.M104617200
37. Rodionov RN, Murry DJ, Vaulman SF, Stevens JW, Lentz SR (2010) Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production. J Biol Chem 285(8):5385-5391. doi: 10.1074/jbc.M109.091280
38. Ronden RA, Houben AJ, Teerlink T, Bakker JA, Bierau J, Stehouwer CD, De Leeuw PW, Kroon AA (2012) Reduced renal plasma clearance does not explain increased plasma asymmetric dimethylarginine in hypertensive subjects with mild to moderate renal insufficiency. Am J Physiol Renal Physiol 303(1):F149-F156. doi: 10.1152/ajprenal.00045.2012
39. Siroen MP, Warle MC, Teerlink T, Nijveldt RJ, Kuipers EJ, Metselaar HJ, Tilanus HW, Kuik DJ, van der Sijp JR, Meijer S, van der Hoven B, van Leeuwen PA (2004) The transplanted liver graft is capable of clearing asymmetric dimethylarginine. Liver Transpl 10(12):1524-1530. doi: 10.1002/lt.20286
40. Siroen MP, van der Sijp JR, Teerlink T, van Schaik C, Nijveldt RJ, van Leeuwen PA (2005) The human liver clears both asymmetric and symmetric dimethylarginine. Hepatology 41(3):559-565. doi: 10.1002/hep.20579
41. Strobel J, Mieth M, Endress B, Auge D, König J, Fromm MF, Maas R (2012) Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1). J Mol Cell Cardiol 53(3):392-400. doi: 10.1016/j.yjmcc.2012.06.002
42. Tang J, Frankel A, Cook RJ, Kim S, Paik WK, Williams KR, Clarke S, Herschman HR (2000) PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells. J Biol Chem 275(11):7723-7730
43. Teerlink T, Luo Z, Palm F, Wilcox CS (2009) Cellular ADMA: regulation and action. Pharmacol Res 60(6):448-460. doi: 10.1016/j.phrs.2009.08.002
44. Tojo A, Welch WJ, Bremer V, Kimoto M, Kimura K, Omata M, Ogawa T, Vallance P, Wilcox CS (1997) Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 52(6):1593-1601
45. Tsikas D, Böger RH, Sandmann J, Bode-Böger SM, Fröhlich JC (2000) Endogenous nitric oxide synthase inhibitors are responsible for the l-arginine paradox. FEBS Lett 478(1-2):1-3
46. Tsuda M, Terada T, Asaka J, Ueba M, Katsura T, Inui K (2007) Oppositely directed H+ gradient functions as a driving force of rat H+/organic cation antiporter MATE1. Am J Physiol Renal Physiol 292(2):F593-F598. doi: 10.1152/ajprenal.00312.2006
47. Vallance P, Leiper J (2004) Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 24(6):1023-1030. doi: 10.1161/01.ATV.0000128897.54893.26
48. Vallance P, Leone A, Calver A, Collier J, Moncada S (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339(8793):572-575. doi: 10.1016/0140-6736(92)90865-Z
49. Visigalli R, Barilli A, Bussolati O, Sala R, Gazzola GC, Parolari A, Tremoli E, Simon A, Closs EI, Dall'Asta V (2007) Rapamycin stimulates arginine influx through CAT2 transporters in human endothelial cells. Biochim Biophys Acta 1768(6):1479-1487. doi: 10.1016/j.bbamem.2007.02.016
50. White MF, Christensen HN (1982) The two-way flux of cationic amino acids across the plasma membrane of mammalian cells is largely explained by a single transport system. J Biol Chem 257(17):10069-10080
51. Winter TN, Elmquist WF, Fairbanks CA (2011) OCT2 and MATE1 provide bidirectional agmatine transport. Mol Pharm 8(1):133-142. doi: 10.1021/mp100180a
52. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich J, Böger R (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358(9299):2113-2117
53. Zolk O, Solbach TF, König J, Fromm MF (2009) Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs Arch Pharmacol 379(4):337-348. doi: 10.1007/s00210-008-0369-5